- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01168414
A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
July 7, 2011 updated by: Ministry of Health, Malaysia
A Randomized, Comparison of the Effects of Ganfort and Duotrav on Intraocular Pressure in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Open Label/Evaluator-blind/Cross-over Study
This is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8 weeks each.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wilayah Persekutuan
-
Kuala Lumpur, Wilayah Persekutuan, Malaysia, 50586
- Ophthalmology Department, Hospital Kuala Lumpur
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Visual acuity 6/60 or better
- Patients who are controlled (IOP < 21 mmHg) on non-fixed combination of Latanoprost & Timolol for at least 3 months before the baseline visit and
- Patients on mono-therapy either Latanoprost or Timolol who are eligible for dual therapy being not satisfactorily controlled (IOP>21mmHG)
Exclusion Criteria:
- Angle closure glaucoma
- Neovascular Galucoma
- Secondary open angle glaucoma
- Ocular infection/inflammation within 3 months
- Ocular surgery within 3 months
- History of Refractive surgery
- Argon laser trabeculoplasty/Selective laser trabeculoplasty
- Pregnancy/nursing
- Hypersensitivity to benzalkonium chloride or to any other components of the trial drugs solution.
- Patients in whom beta-blockers are contraindicated
- Patients on any drugs known to affect IOP.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ganfort
Fixed combination of Bimatoprost and Timolol
|
Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
|
Active Comparator: Duotrav
Fixed combination of Travoprost and Timolol
|
Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean intraocular pressure of the 12-hour IOP curve
Time Frame: 8 weeks
|
To compare the mean intraocular pressure of the 12-hour IOP curve for Ganfort and Duotrav
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean intraocular pressure
Time Frame: 12 hours
|
Difference in mean IOP for Ganfort and Duotrav
|
12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
July 21, 2010
First Submitted That Met QC Criteria
July 22, 2010
First Posted (Estimate)
July 23, 2010
Study Record Updates
Last Update Posted (Estimate)
July 8, 2011
Last Update Submitted That Met QC Criteria
July 7, 2011
Last Verified
July 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMRR-10-466-5929
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
Clinical Trials on Ganfort
-
Allergan S.A. DE C.V..Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleGermany, Netherlands
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited Kingdom, Spain, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland
-
AllerganCompletedOcular Hypertension | Glaucoma, Primary Open AngleGermany
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleChina
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleKorea, Republic of
-
Larissa University HospitalCompletedOcular Hypertension | GlaucomaGreece
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria